The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
“We need all the capital we can get our hands on," the company states.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
